Promazine
General information:
| Withdrawn ID: | 183 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | N05AA03 |
| Molecular Formula: | C17H20N2S |
| Molweight: | 284.419 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | No |
|---|---|
| First approved: | 1956 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Promazine as primary suspect: | 1 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 1 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| Incorrect dose administered | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P04637 | 10000 | Cellular tumor antigen p53 | P53_HUMAN |
| P16473 | 39.8 | Thyrotropin receptor | TSHR_HUMAN |
| P35367 | 2454.71 | Histamine H1 receptor | HRH1_HUMAN |
| Q16665 | 5011.9 | Hypoxia-inducible factor 1-alpha | HIF1A_HUMAN |
Toxicity information:
| Toxicity class: | 3 |
|---|---|
| Toxicity type: | N/A |
| LD50: | 210 mg/kg |
External links:
| ChEBML: | CHEMBL564 |
|---|---|
| DrugBank: | DB00420 |